CellaVision AB (publ) (CEVI.ST)
SEK 222.0
(2.07%)
SEK 222.0
(2.07%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -56.94 Million SEK | -924.51% |
| 2022 | -5.55 Million SEK | -187.28% |
| 2021 | 6.36 Million SEK | -79.13% |
| 2020 | 30.51 Million SEK | -57.25% |
| 2019 | 71.38 Million SEK | 143.47% |
| 2018 | -164.22 Million SEK | -7.4% |
| 2017 | -152.91 Million SEK | -20.03% |
| 2016 | -127.4 Million SEK | -20.69% |
| 2015 | -105.55 Million SEK | -103.37% |
| 2014 | -51.9 Million SEK | -36.94% |
| 2013 | -37.9 Million SEK | -18.58% |
| 2012 | -31.96 Million SEK | 15.67% |
| 2011 | -37.9 Million SEK | -180585.71% |
| 2010 | 21 Thousand SEK | 100.39% |
| 2009 | -5.34 Million SEK | -269.58% |
| 2008 | 3.15 Million SEK | 145.61% |
| 2007 | -6.91 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -77.28 Million SEK | -29.81% |
| 2024 Q3 | -102.27 Million SEK | -32.34% |
| 2024 Q1 | -59.53 Million SEK | -4.55% |
| 2023 Q4 | -56.94 Million SEK | -225.35% |
| 2023 Q1 | 41.76 Million SEK | 851.39% |
| 2023 Q2 | 98.16 Million SEK | 135.05% |
| 2023 FY | -56.94 Million SEK | -924.51% |
| 2023 Q3 | 45.42 Million SEK | -53.72% |
| 2022 Q2 | 57.69 Million SEK | 94.01% |
| 2022 Q4 | -5.55 Million SEK | -112.67% |
| 2022 FY | -5.55 Million SEK | -187.28% |
| 2022 Q1 | 29.73 Million SEK | 367.01% |
| 2022 Q3 | 43.87 Million SEK | -23.97% |
| 2021 Q4 | 6.36 Million SEK | -87.78% |
| 2021 Q1 | 55.77 Million SEK | 82.78% |
| 2021 FY | 6.36 Million SEK | -79.13% |
| 2021 Q2 | 40.37 Million SEK | -27.61% |
| 2021 Q3 | 52.09 Million SEK | 29.02% |
| 2020 Q2 | 40.47 Million SEK | -44.34% |
| 2020 Q1 | 72.72 Million SEK | 1.89% |
| 2020 FY | 30.51 Million SEK | -57.25% |
| 2020 Q4 | 30.51 Million SEK | -39.96% |
| 2020 Q3 | 50.82 Million SEK | 25.56% |
| 2019 Q1 | -142.86 Million SEK | 13.0% |
| 2019 Q2 | -116.63 Million SEK | 18.36% |
| 2019 Q4 | 71.38 Million SEK | 150.4% |
| 2019 Q3 | -141.63 Million SEK | -21.44% |
| 2019 FY | 71.38 Million SEK | 143.47% |
| 2018 Q1 | -121.25 Million SEK | 20.71% |
| 2018 Q4 | -164.22 Million SEK | -30.49% |
| 2018 FY | -164.22 Million SEK | -7.4% |
| 2018 Q3 | -125.85 Million SEK | -20.9% |
| 2018 Q2 | -104.09 Million SEK | 14.15% |
| 2017 FY | -152.91 Million SEK | -20.03% |
| 2017 Q4 | -152.91 Million SEK | -64.01% |
| 2017 Q2 | -94.58 Million SEK | 20.36% |
| 2017 Q1 | -118.75 Million SEK | 6.79% |
| 2017 Q3 | -93.23 Million SEK | 1.42% |
| 2016 Q1 | -95.68 Million SEK | 9.36% |
| 2016 Q3 | -74.19 Million SEK | -4.89% |
| 2016 Q4 | -127.4 Million SEK | -71.72% |
| 2016 Q2 | -70.73 Million SEK | 26.08% |
| 2016 FY | -127.4 Million SEK | -20.69% |
| 2015 Q2 | -40.98 Million SEK | 29.45% |
| 2015 Q4 | -105.55 Million SEK | -44.35% |
| 2015 FY | -105.55 Million SEK | -103.37% |
| 2015 Q1 | -58.09 Million SEK | -23.4% |
| 2015 Q3 | -73.12 Million SEK | -78.44% |
| 2014 Q3 | -33.14 Million SEK | -51.91% |
| 2014 Q4 | -47.07 Million SEK | -42.03% |
| 2014 Q1 | -44.94 Million SEK | -18.58% |
| 2014 FY | -51.9 Million SEK | -36.94% |
| 2014 Q2 | -21.82 Million SEK | 51.45% |
| 2013 FY | -37.9 Million SEK | -18.58% |
| 2013 Q1 | -13.2 Million SEK | 58.7% |
| 2013 Q3 | -9.56 Million SEK | -99.15% |
| 2013 Q4 | -37.9 Million SEK | -296.2% |
| 2013 Q2 | -4.8 Million SEK | 63.61% |
| 2012 Q4 | -31.96 Million SEK | -66.76% |
| 2012 Q2 | -22.49 Million SEK | 29.97% |
| 2012 Q1 | -32.11 Million SEK | 15.26% |
| 2012 FY | -31.96 Million SEK | 15.67% |
| 2012 Q3 | -19.16 Million SEK | 14.78% |
| 2011 FY | -37.9 Million SEK | -180585.71% |
| 2011 Q4 | -37.9 Million SEK | -114.56% |
| 2011 Q3 | -17.66 Million SEK | -87.41% |
| 2011 Q1 | -12.38 Million SEK | -59061.9% |
| 2011 Q2 | -9.42 Million SEK | 23.87% |
| 2010 Q1 | -1.08 Million SEK | 79.73% |
| 2010 Q2 | -2.14 Million SEK | -97.42% |
| 2010 FY | 21 Thousand SEK | 100.39% |
| 2010 Q3 | -685 Thousand SEK | 67.99% |
| 2010 Q4 | 21 Thousand SEK | 103.07% |
| 2009 Q3 | 13.45 Million SEK | 30.15% |
| 2009 FY | -5.34 Million SEK | -269.58% |
| 2009 Q2 | 10.33 Million SEK | 0.0% |
| 2009 Q4 | -5.34 Million SEK | -139.74% |
| 2008 FY | 3.15 Million SEK | 145.61% |
| 2008 Q4 | 3.15 Million SEK | 0.0% |
| 2007 FY | -6.91 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acarix AB (publ) | -35.14 Million SEK | -62.002% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.641% |
| ADDvise Group AB (publ) | 1.22 Billion SEK | 104.641% |
| Arcoma AB | -1.12 Million SEK | -4948.05% |
| Bactiguard Holding AB (publ) | 109.88 Million SEK | 151.821% |
| BICO Group AB (publ) | 927.9 Million SEK | 106.137% |
| Boule Diagnostics AB (publ) | 128.8 Million SEK | 144.21% |
| Clinical Laserthermia Systems AB (publ) | -14.87 Million SEK | -282.752% |
| Chordate Medical Holding AB (publ) | -8.45 Million SEK | -573.455% |
| C-Rad AB (publ) | -127.6 Million SEK | 55.375% |
| Duearity AB (publ) | 10.23 Million SEK | 656.563% |
| Dignitana AB (publ) | 13.07 Million SEK | 535.436% |
| Episurf Medical AB (publ) | -52.7 Million SEK | -8.049% |
| Getinge AB (publ) | 5.4 Billion SEK | 101.053% |
| Scandinavian Real Heart AB (Publ) | -35.05 Million SEK | -62.445% |
| Iconovo AB (publ) | -10.75 Million SEK | -429.43% |
| Integrum AB (publ) | -10.47 Million SEK | -443.519% |
| Luxbright AB (publ) | -13.83 Million SEK | -311.625% |
| Mentice AB (publ) | -49.56 Million SEK | -14.886% |
| OssDsign AB (publ) | -162.78 Million SEK | 65.021% |
| Paxman AB (publ) | -11.41 Million SEK | -399.01% |
| Promimic AB (publ) | -50.32 Million SEK | -13.153% |
| Qlife Holding AB (publ) | 19.07 Million SEK | 398.595% |
| SciBase Holding AB (publ) | -27.32 Million SEK | -108.396% |
| ScandiDos AB (publ) | -1.53 Million SEK | -3619.268% |
| Sectra AB (publ) | -772.85 Million SEK | 92.632% |
| Sedana Medical AB (publ) | -226.87 Million SEK | 74.901% |
| Senzime AB (publ) | -139.54 Million SEK | 59.193% |
| SpectraCure AB (publ) | -50.23 Million SEK | -13.354% |
| Stille AB | -178.5 Million SEK | 68.1% |
| Vitrolife AB (publ) | 1.22 Billion SEK | 104.637% |
| Xvivo Perfusion AB (publ) | -214.65 Million SEK | 73.472% |